サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1704473

移植片対宿主病（GVHD）治療の世界市場レポート 2025年

Graft Versus Host Disease (GVHD) Treatment Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
移植片対宿主病（GVHD）治療の世界市場レポート 2025年
出版日: 2025年04月01日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

移植片対宿主病（GVHD）治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.5％で41億米ドルに成長します。予測期間の成長は、同種移植数の増加、急性GVHDの発生率の増加、造血幹細胞治療率の増加、骨髄移植需要の増加、世界のGVHD有病率の上昇、慢性GVHD症例の増加、技術の進歩、患者数の増加などに起因します。予測期間における主な動向としては、パートナーシップ、投資、製品承認、カスタマイズなどが挙げられます。

予測される血液疾患の増加は、当面の移植片対宿主病（GVHD）治療市場の成長を牽引すると予想されます。血液疾患は、血液とその成分に影響を及ぼすさまざまな疾患を包含しており、不健康な生活習慣、遺伝的素因、放射線、化学物質、汚染物質などの環境毒素への曝露などの要因によって、より一般的になってきています。GVHDを管理するために開発された治療戦略は、血液疾患患者にとってより広範な意味を持ち、免疫調節や疾患管理の改善に新たな機会をもたらします。例えば、白血病リンパ腫協会の2023年報告書によると、2023年には米国で白血病、リンパ腫、骨髄腫により約5万7,380人が死亡すると予測されています。これは1日あたりおよそ157人、1時間に6人以上が血液がんで死亡していることに相当します。このように、血液疾患の有病率の増加が移植片対宿主病（GVHD）治療市場の原動力となっています。

GVHD治療市場の主なプレーヤーは、競争優位に立つために先進的な薬剤を積極的に開発し、規制当局の承認を求めています。製品承認は、ヘルスケア製品が患者に提供される前に、安全性、有効性、品質に関する必要な基準を満たすことを保証する上で重要な役割を果たしています。例えば、2023年3月、米国のヘルスケア企業であるIncyte Corporationは、JAK1/JAK2阻害剤であるルキソリチニブ徐放（XR）錠を開発し、特定のタイプの骨髄線維症、真性多血症、移植片対宿主病（GVHD）の治療薬として1日1回投与の承認を食品医薬品局（FDA）から取得しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界移植片対宿主病（GVHD）治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の移植片対宿主病（GVHD）治療市場：成長率分析
  • 世界の移植片対宿主病（GVHD）治療市場の実績：規模と成長, 2019-2024
  • 世界の移植片対宿主病（GVHD）治療市場の予測：規模と成長, 2024-2029, 2034F
  • 世界移植片対宿主病（GVHD）治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の移植片対宿主病（GVHD）治療市場：製品タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • コルチコステロイド
  • モノクローナル抗体
  • 免疫抑制剤
  • その他
  • 世界の移植片対宿主病（GVHD）治療市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 急性GVHD
  • GVHDの予防
  • 慢性GVHD
  • 世界の移植片対宿主病（GVHD）治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の移植片対宿主病（GVHD）治療市場コルチコステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • プレドニゾロン
  • メチルプレドニゾロン
  • デキサメタゾン
  • ヒドロコルチゾン
  • ベタメタゾン
  • ブデソニド
  • 世界の移植片対宿主病（GVHD）治療市場モノクローナル抗体の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗INFモノクローナル抗体（インフリキシマブ、アダリムマブ）
  • 抗IL-2Raモノクローナル抗体（バシリキシマブ）
  • 抗CD52モノクローナル抗体（アレムツズマブ）
  • 抗IL-6モノクローナル抗体（トシリズマブ）
  • 抗CD20モノクローナル抗体（リツキシマブ）
  • 世界の移植片対宿主病（GVHD）治療市場免疫抑制剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • カルシニューリン阻害剤（シクロスポリン、タクロリムス）
  • メトトレキサート
  • ミコフェノール酸モフェチル
  • アザチオプリン
  • シロリムス（ラパマイシン）
  • シクロホスファミド
  • 世界の移植片対宿主病（GVHD）治療市場、その他、タイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 間葉系幹細胞（MSC）
  • JAK阻害剤（ルキソリチニブ）
  • 体外フォトフェレシス（ECP）
  • サリドマイド
  • 抗胸腺細胞グロブリン（ATG）
  • コロニー刺激因子（フィルグラスチム）

第7章 地域別・国別分析

  • 世界の移植片対宿主病（GVHD）治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の移植片対宿主病（GVHD）治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 移植片対宿主病（GVHD）治療市場：競合情勢
  • 移植片対宿主病（GVHD）治療市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Novartis AG
  • Bristol Myers Squibb
  • AstraZeneca
  • Abbott Laboratories
  • GlaxoSmithKline plc
  • Eli Lilly And Company
  • Novo Nordisk A/S
  • Takeda Pharmaceutical Company Limited
  • Gilead Sciences Inc.
  • Merck KGaA
  • Teva Pharmaceutical Industries Ltd.
  • Biogen Inc.
  • Astellas Pharma Inc.
  • Jazz Pharmaceuticals plc
  • Allergan plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 移植片対宿主病（GVHD）治療市場2029：新たな機会を提供する国
  • 移植片対宿主病（GVHD）治療市場2029：新たな機会を提供するセグメント
  • 移植片対宿主病（GVHD）治療市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r30334

Graft versus host disease (GVHD) treatment encompasses a range of medical interventions designed to manage or mitigate the complications stemming from GVHD, a condition wherein transplanted donor cells attack the recipient's tissues. These treatments are employed to address the ramifications of GVHD, a disease characterized by the recipient's tissues being targeted by transplanted donor cells.

The primary product types utilized in graft versus host disease (GVHD) treatment include corticosteroids, monoclonal antibodies, immunosuppressants, among others. Corticosteroids are a class of steroid hormones produced in the adrenal cortex of vertebrates, as well as synthetic analogues of these hormones. GVHD treatment addresses various disease types such as acute GVHD, prophylaxis GVHD, and chronic GVHD. These treatments are utilized by diverse end users including hospital pharmacies, retail pharmacies, and online pharmacies.

The graft versus host disease (GVHD) treatment market research report is one of a series of new reports from The Business Research Company that provides graft versus host disease (GVHD) treatment market statistics, including graft versus host disease (GVHD) treatment industry global market size, regional shares, competitors with a graft versus host disease (GVHD) treatment market share, detailed graft versus host disease (GVHD) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the graft versus host disease (GVHD) treatment industry. This graft versus host disease (GVHD) treatment research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The graft versus host disease (GVHD) treatment market size has grown strongly in recent years. It will grow from $2.85 billion in 2024 to $3.07 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. The growth in the historic period can be attributed to increase in number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in patient population.

The graft versus host disease (GVHD) treatment market size is expected to see strong growth in the next few years. It will grow to $4.1 billion in 2029 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to Increase in the number of allogeneic transplantations, growing incidence of acute GVHD, increasing the rate of hematopoietic stem cell treatment, rising demand for bone marrow transplants, rising prevalence of GVHD worldwide, increase in chronic GVHD cases, advancements in technology, rise in the patient population. Major trends in the forecast period include partnerships, investment, product approvals, and customizations.

The anticipated rise in hematological disorders is expected to drive the growth of the graft versus host disease (GVHD) treatment market in the foreseeable future. Hematological disorders, which encompass various conditions affecting the blood and its components, are becoming more prevalent due to factors such as unhealthy lifestyle habits, genetic predisposition, and exposure to environmental toxins such as radiation, chemicals, and pollutants. Treatment strategies developed for managing GVHD can have broader implications for patients with hematological disorders, presenting new opportunities for immune modulation and improved disease management. For example, according to the Leukemia & Lymphoma Society's 2023 report, leukemia, lymphoma, and myeloma are projected to cause the deaths of approximately 57,380 people in the US in 2023. This equates to roughly 157 individuals per day or more than six deaths every hour from blood cancer. Thus, the increasing prevalence of hematological disorders is a driving force behind the graft versus host disease (GVHD) treatment market.

Key players in the GVHD treatment market are actively developing advanced drugs and seeking regulatory approval to gain a competitive edge. Product approvals play a crucial role in ensuring that healthcare products meet the necessary standards for safety, efficacy, and quality before they are made available to patients. For instance, in March 2023, Incyte Corporation, a US-based healthcare company, developed ruxolitinib extended-release (XR) tablets, a JAK1/JAK2 inhibitor, which received approval from the Food and Drug Administration (FDA) for once-daily use in treating specific types of myelofibrosis, polycythemia vera, and graft-versus-host disease (GVHD).

In March 2024, Lonza Group Ltd, a Switzerland-based healthcare manufacturing company, acquired Roche's biologics manufacturing site for $1.2 billion. With this acquisition, Lonza aims to expand its portfolio by incorporating Roche's expertise in the treatment of graft-versus-host disease (GVHD). F. Hoffmann-La Roche AG, a Switzerland-based company, specializes in providing treatment options for GVHD, a condition that can occur after stem cell or bone marrow transplants.

Major companies operating in the graft versus host disease (GVHD) treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi SA, Novartis AG, Bristol Myers Squibb, AstraZeneca, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly And Company, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Biogen Inc., Astellas Pharma Inc., Jazz Pharmaceuticals plc, Allergan plc, Incyte Corporation, Mallinckrodt Pharmaceuticals, Genzyme Corporation, Kiadis Pharma, Neovii Pharmaceuticals AG, ElsaLys Biotech SA, Mesoblast Ltd., Soligenix

North America was the largest region in the graft versus host disease (GVHD) treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the graft versus host disease (GVHD) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the graft versus host disease (GVHD) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The graft versus host disease (GVHD) treatment market includes revenues earned by entities by immunosuppressive medications, clinical trials, specialized therapies and stem cell transplantation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Graft Versus Host Disease (GVHD) Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on graft versus host disease (gvhd) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for graft versus host disease (gvhd) treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The graft versus host disease (gvhd) treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product Type: Corticosteroids; Monoclonal Antibodies; Immunosuppressants; Others
  • 2) By Disease Type: Acute GvHD; Prophylaxis GvHD; Chronic GvHD
  • 3) By End User: Hospitals Pharmacies; Retail Pharmacies; Online Pharmacies
  • Subsegments:
  • 1) By Corticosteroids: Prednisolone; Methylprednisolone; Dexamethasone; Hydrocortisone; Betamethasone; Budesonide
  • 2) By Monoclonal Antibodies: Anti-Inf Monoclonal Antibodies ( Infliximab, Adalimumab); Anti-il-2ra Monoclonal Antibodies ( Basiliximab); Anti-cd52 Monoclonal Antibodies (Alemtuzumab); Anti-il-6 Monoclonal Antibodies (Tocilizumab); Anti-Cd20 Monoclonal Antibodies (Rituximab)
  • 3) By Immunosuppressants: Calcineurin Inhibitors (Cyclosporine, Tacrolimus); Methotrexate; Mycophenolate Mofetil; Azathioprine; Sirolimus (Rapamycin); Cyclophosphamide
  • 4) By Others: Mesenchymal Stem Cells (Mscs); Jak Inhibitors ( Ruxolitinib); Extracorporeal Photopheresis (Ecp); Thalidomide; Antithymocyte Globulin (Atg); Colony-Stimulating Factors (Filgrastim)
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Sanofi SA
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Graft Versus Host Disease (GVHD) Treatment Market Characteristics

3. Graft Versus Host Disease (GVHD) Treatment Market Trends And Strategies

4. Graft Versus Host Disease (GVHD) Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Graft Versus Host Disease (GVHD) Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Graft Versus Host Disease (GVHD) Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Graft Versus Host Disease (GVHD) Treatment Market Growth Rate Analysis
  • 5.4. Global Graft Versus Host Disease (GVHD) Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Graft Versus Host Disease (GVHD) Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Graft Versus Host Disease (GVHD) Treatment Total Addressable Market (TAM)

6. Graft Versus Host Disease (GVHD) Treatment Market Segmentation

  • 6.1. Global Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Corticosteroids
  • Monoclonal Antibodies
  • Immunosuppressants
  • Others
  • 6.2. Global Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Acute GvHD
  • Prophylaxis GvHD
  • Chronic GvHD
  • 6.3. Global Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Graft Versus Host Disease (GVHD) Treatment Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Prednisolone
  • Methylprednisolone
  • Dexamethasone
  • Hydrocortisone
  • Betamethasone
  • Budesonide
  • 6.5. Global Graft Versus Host Disease (GVHD) Treatment Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Anti-INF Monoclonal Antibodies (Infliximab, Adalimumab)
  • Anti-IL-2Ra Monoclonal Antibodies (Basiliximab)
  • Anti-CD52 Monoclonal Antibodies (Alemtuzumab)
  • Anti-IL-6 Monoclonal Antibodies (Tocilizumab)
  • Anti-CD20 Monoclonal Antibodies (Rituximab)
  • 6.6. Global Graft Versus Host Disease (GVHD) Treatment Market, Sub-Segmentation Of Immunosuppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Calcineurin Inhibitors (Cyclosporine, Tacrolimus)
  • Methotrexate
  • Mycophenolate Mofetil
  • Azathioprine
  • Sirolimus (Rapamycin)
  • Cyclophosphamide
  • 6.7. Global Graft Versus Host Disease (GVHD) Treatment Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Mesenchymal Stem Cells (MSCs)
  • JAK Inhibitors (Ruxolitinib)
  • Extracorporeal Photopheresis (ECP)
  • Thalidomide
  • Antithymocyte Globulin (ATG)
  • Colony-Stimulating Factors (Filgrastim)

7. Graft Versus Host Disease (GVHD) Treatment Market Regional And Country Analysis

  • 7.1. Global Graft Versus Host Disease (GVHD) Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Graft Versus Host Disease (GVHD) Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market

  • 8.1. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Graft Versus Host Disease (GVHD) Treatment Market

  • 9.1. China Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 9.2. China Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Graft Versus Host Disease (GVHD) Treatment Market

  • 10.1. India Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Graft Versus Host Disease (GVHD) Treatment Market

  • 11.1. Japan Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 11.2. Japan Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Graft Versus Host Disease (GVHD) Treatment Market

  • 12.1. Australia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Graft Versus Host Disease (GVHD) Treatment Market

  • 13.1. Indonesia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Graft Versus Host Disease (GVHD) Treatment Market

  • 14.1. South Korea Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 14.2. South Korea Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Graft Versus Host Disease (GVHD) Treatment Market

  • 15.1. Western Europe Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 15.2. Western Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Graft Versus Host Disease (GVHD) Treatment Market

  • 16.1. UK Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Graft Versus Host Disease (GVHD) Treatment Market

  • 17.1. Germany Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Graft Versus Host Disease (GVHD) Treatment Market

  • 18.1. France Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Graft Versus Host Disease (GVHD) Treatment Market

  • 19.1. Italy Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Graft Versus Host Disease (GVHD) Treatment Market

  • 20.1. Spain Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market

  • 21.1. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 21.2. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Graft Versus Host Disease (GVHD) Treatment Market

  • 22.1. Russia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Graft Versus Host Disease (GVHD) Treatment Market

  • 23.1. North America Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 23.2. North America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Graft Versus Host Disease (GVHD) Treatment Market

  • 24.1. USA Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 24.2. USA Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Graft Versus Host Disease (GVHD) Treatment Market

  • 25.1. Canada Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 25.2. Canada Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Graft Versus Host Disease (GVHD) Treatment Market

  • 26.1. South America Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 26.2. South America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Graft Versus Host Disease (GVHD) Treatment Market

  • 27.1. Brazil Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Graft Versus Host Disease (GVHD) Treatment Market

  • 28.1. Middle East Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 28.2. Middle East Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Graft Versus Host Disease (GVHD) Treatment Market

  • 29.1. Africa Graft Versus Host Disease (GVHD) Treatment Market Overview
  • 29.2. Africa Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Graft Versus Host Disease (GVHD) Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Graft Versus Host Disease (GVHD) Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Graft Versus Host Disease (GVHD) Treatment Market Competitive Landscape
  • 30.2. Graft Versus Host Disease (GVHD) Treatment Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis

31. Graft Versus Host Disease (GVHD) Treatment Market Other Major And Innovative Companies

  • 31.1. Novartis AG
  • 31.2. Bristol Myers Squibb
  • 31.3. AstraZeneca
  • 31.4. Abbott Laboratories
  • 31.5. GlaxoSmithKline plc
  • 31.6. Eli Lilly And Company
  • 31.7. Novo Nordisk A/S
  • 31.8. Takeda Pharmaceutical Company Limited
  • 31.9. Gilead Sciences Inc.
  • 31.10. Merck KGaA
  • 31.11. Teva Pharmaceutical Industries Ltd.
  • 31.12. Biogen Inc.
  • 31.13. Astellas Pharma Inc.
  • 31.14. Jazz Pharmaceuticals plc
  • 31.15. Allergan plc

32. Global Graft Versus Host Disease (GVHD) Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Graft Versus Host Disease (GVHD) Treatment Market

34. Recent Developments In The Graft Versus Host Disease (GVHD) Treatment Market

35. Graft Versus Host Disease (GVHD) Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Graft Versus Host Disease (GVHD) Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Graft Versus Host Disease (GVHD) Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Graft Versus Host Disease (GVHD) Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer